Literature DB >> 2614472

Comparison of the regional distribution of transferrin receptors and aluminium in the forebrain of chronic renal dialysis patients.

C M Morris1, J M Candy, A E Oakley, G A Taylor, S Mountfort, H Bishop, M K Ward, C A Bloxham, J A Edwardson.   

Abstract

Recent studies have emphasised the potential neurotoxicity of aluminium in dialysis encephalopathy and it has also been suggested that this element may have a role in the pathogenesis of Alzheimer's disease. Aluminium is known to be transported by the iron transport protein transferrin. In this study using receptor autoradiography we have demonstrated the presence of transferrin binding sites in the human forebrain and shown a pattern similar to that found in other species. Imaging secondary ion mass spectrometry has demonstrated the distribution of aluminium-containing cell-like profiles in the brains of chronic renal dialysis patients who have raised levels of brain aluminium (greater than 4 micrograms/g dry weight) and even in dialysis patients where the gross level of aluminium was within the normal range. The density of these profiles corresponded to the regions of high transferrin receptor density. In contrast, the distribution of iron in the brain showed an inverse correlation with transferrin receptor density with highest iron levels present in the globus pallidus, an area of low transferrin receptor density. These results suggest that the regional distribution of neuropathological changes seen in dialysis encephalopathy patients and also Alzheimer's disease may reflect the distribution of transferrin receptors. The discrepancy between iron distribution and transferrin receptor distribution suggests that further, as yet uncharacterized mechanisms, govern the distribution of brain iron.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2614472     DOI: 10.1016/0022-510x(89)90238-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  Role of manganese in neurodegenerative diseases.

Authors:  Aaron B Bowman; Gunnar F Kwakye; Elena Herrero Hernández; Michael Aschner
Journal:  J Trace Elem Med Biol       Date:  2011-10-01       Impact factor: 3.849

Review 2.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

3.  Visceral Aluminum Deposition In Chronic Renal Insufficiency. (Light Microscopy and X-ray Microanalysis).

Authors:  Attila Patonai; András Csikós; György Deák
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

4.  Cholinergic system under aluminium toxicity in rat brain.

Authors:  K Yellamma; S Saraswathamma; B Nirmala Kumari
Journal:  Toxicol Int       Date:  2010-07

5.  Dialysis-associated encephalopathy: light and electron microscopic morphology and topography with evidence of aluminum by laser microprobe mass analysis.

Authors:  E Reusche; U Seydel
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

6.  Germanium-68 as a possible marker for silicon transport in rat brain.

Authors:  G A Taylor; R G Pullen; A B Keith; J A Edwardson
Journal:  Neurochem Res       Date:  1992-12       Impact factor: 3.996

7.  Iron and aluminium in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients.

Authors:  D J Dedman; A Treffry; J M Candy; G A Taylor; C M Morris; C A Bloxham; R H Perry; J A Edwardson; P M Harrison
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

Review 8.  Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.

Authors:  D C Dorman; S L Allen; J Z Byczkowski; L Claudio; J E Fisher; J W Fisher; G J Harry; A A Li; S L Makris; S Padilla; L G Sultatos; B E Mileson
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Cognitive deterioration and associated pathology induced by chronic low-level aluminum ingestion in a translational rat model provides an explanation of Alzheimer's disease, tests for susceptibility and avenues for treatment.

Authors:  J R Walton
Journal:  Int J Alzheimers Dis       Date:  2012-07-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.